Alexion announced that results from its Phase 2 study of Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy. The primary endpoint of the study, change in platelet count, increased significantly through 26 weeks of treatment compared to baseline (p<0.0001) and was increased 96 ± 21 x109/L at 26 weeks of treatment with eculizumab. Researchers reported that following the first infusion of eculizumab, platelet count increased significantly at Day 7 (p=0.02). A key secondary endpoint, TMA event-free status, was achieved in 88% of patients (15 of 17; 95% CI 64-100).

Soliris is a first-in-class terminal complement inhibitor currently approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).

For more information call (203) 272-ALXN or visit